secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2022-08-16T23:59:59+00:00
Accession:  0001104659-22-091744
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS Life Sciences elects Katherine Bach Kalin to its Board of Directors
--------------------------------------------------------------------------

- Elected on Aug 13, 2022 as Class II director, term until 2024 annual meeting.
- Granted option for 19,000 shares at $3.10/share, vesting one year from grant.
- Over 25 years life sciences experience; led corporate strategy at Celgene 2012-2017.
- Also on boards of Genfit (GNFT), Brown Advisory, and FemHealth Ventures.
- Board determined she is independent under SEC and Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000110465922091744/0001104659-22-091744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000110465922091744/tm2223534d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-091744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer